PECAM1 and neoplasm: Results from the quantification of CD31 staining revealed that vascular labeling was significantly reduced in tumours receiving the combined treatment USMB + HT (50 min) at week 1 (VI = 6.92 ± 0.87) (p≤0.05), week 2 (VI = 7.47 ± 0.19) (p≤0.05), week 3 (VI = 6.90 ± 1.88) (p≤0.05) and week 4 (VI = 7.70 ± 0.70) (p≤0.05) compared to USMB only indicating vascular labeling at week 1 (VI = 11.31 ± 1.12), week 2 (VI = 11 ± 0.59), week 3 (VI = 10.65 ± 0.50) and week 4 (VI = 15.38 ± 2.19).